|
🐜
|
Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists
17 auth.
J. Askling,
C. M. Fored,
E. Baecklund,
L. Brandt,
C. Backlin,
A. Ekbom,
C. Sundström,
L. Bertilsson,
L. Cöster,
P. Geborek,
...
L. Jacobsson,
S. Lindblad,
J. Lysholm,
S. Rantapää-Dahlqvist,
T. Saxne,
Lars Klareskog,
N. Feltelius
|
8 |
2005 |
8
🐜
|
|
🐜
|
Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.
15 auth.
J. Askling,
C. M. Fored,
L. Brandt,
E. Baecklund,
L. Bertilsson,
L. Cöster,
P. Geborek,
L. Jacobsson,
S. Lindblad,
J. Lysholm,
...
S. Rantapää-Dahlqvist,
T. Saxne,
V. Romanus,
L. Klareskog,
N. Feltelius
|
8 |
2005 |
8
🐜
|
|
🐜
|
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
14 auth.
J. Askling,
C. M. Fored,
L. Brandt,
E. Baecklund,
L. Bertilsson,
N. Feltelius,
L. Cöster,
P. Geborek,
L. Jacobsson,
S. Lindblad,
...
J. Lysholm,
S. Rantapää-Dahlqvist,
T. Saxne,
Lars Klareskog
|
8 |
2005 |
8
🐜
|
|
🐜
|
Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists
15 auth.
J. Askling,
C. M. Fored,
L. Brandt,
E. Baecklund,
L. Bertilsson,
N. Feltelius,
L. Cöster,
P. Geborek,
L. Jacobsson,
S. Lindblad,
...
J. Lysholm,
S. Rantapää-Dahlqvist,
T. Saxne,
R. V. van Vollenhoven,
L. Klareskog
|
8 |
2007 |
8
🐜
|
|
🐜
|
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register
16 auth.
J. Askling,
E. Baecklund,
Fredrik Granath,
P. Geborek,
M. Fored,
C. Backlin,
L. Bertilsson,
L. Cöster,
L. Jacobsson,
S. Lindblad,
...
J. Lysholm,
S. Rantapää-Dahlqvist,
T. Saxne,
R. Vollenhoven,
Lars Klareskog,
N. Feltelius
|
8 |
2008 |
8
🐜
|
|
🐬
|
Local anti-type II collagen antibody production in rheumatoid arthritis synovial fluid. Evidence for an HLA-DR4-restricted IgG response.
J. Rönnelid,
J. Lysholm,
A. Engström‐Làurent,
L. Klareskog,
B. Heyman
|
7 |
1994 |
7
🐬
|
|
🐜
|
Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept
11 auth.
N. Feltelius,
C. M. Fored,
P. Blomqvist,
L. Bertilsson,
P. Geborek,
L. Jacobsson,
...
S. Lindblad,
J. Lysholm,
S. Rantapää-Dahlqvist,
T. Saxne,
Lars Klareskog
|
6 |
2004 |
6
🐜
|
|
🐬
|
Cathepsin S and cathepsin L in serum and synovial fluid in rheumatoid arthritis with and without autoantibodies.
T. Weitoft,
A. Larsson,
V. Manivel,
J. Lysholm,
A. Knight,
J. Rönnelid
|
5 |
2015 |
5
🐬
|
|
🐜
|
The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice
7 auth.
I. Lekander,
F. Borgström,
J. Lysholm,
R. F. Vollenhoven,
S. Lindblad,
P. Geborek,
...
G. Kobelt
|
4 |
2013 |
4
🐜
|
|
🐜
|
T‐Cell Receptor V‐Gene Usage in Synovial Fluid and Synovial Tissue from RA Patients
8 auth.
S. Gudmundsson,
J. Rönnelid,
A. Karlsson-Parra,
J. Lysholm,
B. Gudbjörnsson,
B. Widenfalk,
...
C. H. Janson,
L. Klareskog
|
4 |
1992 |
4
🐜
|
|
🐬
|
Outcome predictors of intra-articular glucocorticoid treatment for knee synovitis in patients with rheumatoid arthritis – a prospective cohort study
T. Weitoft,
J. Rönnelid,
A. Knight,
J. Lysholm,
T. Saxne,
A. Larsson
|
4 |
2014 |
4
🐬
|
